Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 3;17(3):805-811.
doi: 10.5114/aoms.2019.85252. eCollection 2021.

Active surveillance in prostate cancer management: where do we stand now?

Affiliations

Active surveillance in prostate cancer management: where do we stand now?

Jędrzej Dragan et al. Arch Med Sci. .

Abstract

Prostate cancer (PCa) is the most common cancer in men, with a steadily rising incidence, affecting on average one in six men during their lifetime. The increase in morbidity is related to the increasing overall life expectancy, prostate-specific antigen testing, implementation of new molecular markers for cancer detection and the more frequent application of multiparametric magnetic resonance imaging. There is growing evidence demonstrating that active surveillance (AS) is an alternative to immediate intervention in patients with very low- and low-risk prostate cancer. Ongoing reports from multiple studies have consistently demonstrated a very low rate of metastases and prostate cancer specific mortality in selected cohorts of patients. As a matter of fact, AS has been adopted by many institutions as a safe and effective management strategy. The aim of our review is to summarize the contemporary data on AS in patients affected with PCa with the intention to present the most clinically useful and pertinent AS protocols.

Keywords: active surveillance; molecular markers; multiparametric magnetic resonance imaging; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008;15:3866–71. - PMC - PubMed
    1. Golabek T, Bukowczan J, Sobczynski R, Leszczyszyn J, Chlosta PL. The role of micronutrients in the risk of urinary tract cancer. Arch Med Sci. 2016;12:436–47. - PMC - PubMed
    1. Zlotta AR, Egawa S, Pushkar D, et al. Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst. 2013;105:1050–8. - PubMed
    1. National Institute for Health and Care Excellence . Prostate cancer: diagnosis and management. NICE; 2014. - PubMed
    1. Alam R, Carter HB, Epstein JI, Tosoian JJ. Active surveillance of prostate cancer: current state of practice and utility of multiparametric magnetic resonance imaging. Rev Urol. 2017;19:77–88. - PMC - PubMed